Understanding Australia's influenza pandemic policy on the strategic use of the antiviral drug stockpile

Medical Journal of Australia

Volumn 191, Issue 3, 2009, Pages 136-137

  McCaw, James M ^a   Wood, James G ^b   McBryde, Emma S ^c,d   Nolan, Terry M ^a   Wu, Joseph T ^e   Lipsitch, Marc ^f   McVernon, Jodie ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTIDINE; OSELTAMIVIR; TYROSINE; ZANAMIVIR; ANTIVIRUS AGENT; SIALIDASE;

ANTIBIOTIC RESISTANCE; ARTICLE; DISEASE TRANSMISSION; DRUG STORAGE; GENE MUTATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; PANDEMIC; PROPHYLAXIS; VIRUS STRAIN; ANTIVIRAL RESISTANCE; AUSTRALIA; DRUG ANTAGONISM; DRUG EFFECT; EPIDEMIC; VIROLOGY;

ANTIVIRAL AGENTS; AUSTRALIA; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; HEALTH POLICY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE;

EID: 70349582547     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02720.x     Document Type: Article

References (10)

1. Australian Government Department of Health and Ageing. Australian health management plan for pandemic influenza (2008). Canberra: DoHA, 2008. http://www.flupandemic.gov.au/internet/panflu/publishing.nsf/Content/ahmppi (accessed Jul 2009).
2. Becker NG, Glass K, Barnes B, et al. Using mathematical models to assess responses to an outbreak of an emerged viral respiratory disease. Final report to the Australian Government Department of Health and Ageing. Canberra: National Centre for Epidemiology and Population Health, Australian National University, 2006.
3. Halloran ME, Hayden FG, Yang Y, et al. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 2007; 165: 212-221. (Pubitemid 46096383)
4. Ferguson NM, Cummings DAT, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006; 442: 448-452.
5. Longini I, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005; 309: 1083-1087.
6. McCaw JM, McVernon J. Prophylaxis or treatment? Optimal use of an antiviral stockpile during an influenza pandemic. Math Biosci 2007; 209: 336-360. (Pubitemid 47390908)
7. International Society for Infectious Diseases. ProMED-mail Archive Number 20090630.2359. PRO/AH/EDR Influenza A (H1N1) - worldwide (78): Tamiflu resistance, DK. 30 Jun 2009. http://www.promedmail.org/pls/otn/f?p=2400:1001: 3406131671527906::NO::F2400-P1001-BACK-PAGE,F2400-P1001-PUB-MAIL-ID:1004,78150 (accessed Jul 2009).
8. McCaw JM, Wood JG, McCaw CT, McVernon J. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS One 2008; 3: e2362.
9. Wu JT, Leung GM, Lipsitch M, et al. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 2009; 6: e1000085.
10. Fraser C, Donnelly CA, Cauchemez S, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324: 1557-1561.